ALS

Alpha Cognition Announces Overnight Marketed Offering

Wednesday, September 22, 2021 - 10:08pm

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of units (the “Units”) of the Company.

Key Points: 
  • NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
    VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (Alpha or the Company) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced an overnight marketed public offering (the Offering) of units (the Units) of the Company.
  • The Offering will be conducted pursuant to the Companys Canadian base shelf prospectus dated August 25, 2021 (the Base Shelf Prospectus).
  • A prospectus supplement (the Prospectus Supplement) relating to the Offering will be filed in each of the provinces of Canada, except the Province of Quebec.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some 'War on Drugs' Impacts

Wednesday, September 22, 2021 - 1:50pm

If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin.

Key Points: 
  • If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin.
  • In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus.
  • Tryp'sIND application has details on the safety of the drug product, the study protocol, informed consent information for patients, and additional information.
  • The company expects that the psilocybin oral formulation will increase neuroplasticity and therefore, help create healthy neural patterns of hunger and eating.

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some 'War on Drugs' Impacts

Wednesday, September 22, 2021 - 1:50pm

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- The global need for effective mental health treatment has led to the growing push for the legalization of psychedelic therapies, pushing the market into the mainstream. Last week, Michigan Senator Jeff Irwin introduced legislation that would decriminalize the use of mescaline and psilocybin. If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin. In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus. This legislation coupled with the growing body of research that proves the effectiveness of psychedelics against mental health conditions is among the reasons pushing the psychedelic market towards $69 billion by 2026 . As this happens, companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Cybin Inc. (NEO:CYBN), Compass Pathways (NASDAQ:CMPS), PhamaTher (OTCQB:PHRRF) (CSE:PHRM), and Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED) are pushing R&D efforts to develop and test psychedelic therapies for different health conditions. 

Key Points: 
  • If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin.
  • In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus.
  • Tryp'sIND application has details on the safety of the drug product, the study protocol, informed consent information for patients, and additional information.
  • The company expects that the psilocybin oral formulation will increase neuroplasticity and therefore, help create healthy neural patterns of hunger and eating.

$8.4 Bn CRISPR Markets - Global Forecasts from 2021 to 2026: Escalating R&D to Provide Opportunities Market Players - ResearchAndMarkets.com

Tuesday, September 21, 2021 - 12:25pm

The global CRISPR market is a growing with major investments from developed countries.

Key Points: 
  • The global CRISPR market is a growing with major investments from developed countries.
  • The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward.
  • The escalating geriatric population, Changes in lifestyles, and investment in cutting-edge research technologies are also augmenting the market size.
  • A lot of research and development happening in the market is anticipated to boost the opportunities through the inclining market trends.

The ALS Association Creates thinkALS Tool to Help Doctors Speed Up Diagnosis Process

Tuesday, September 21, 2021 - 1:03pm

WASHINGTON, Sept. 21, 2021 /PRNewswire/ -- The ALS Association has created a new diagnostic guide, thinkALS , that will help neurologists more quickly diagnose ALS.

Key Points: 
  • WASHINGTON, Sept. 21, 2021 /PRNewswire/ -- The ALS Association has created a new diagnostic guide, thinkALS , that will help neurologists more quickly diagnose ALS.
  • The ALS Association has created a new diagnostic guide, thinkALS, that will help neurologists diagnose ALS more quickly.
  • "Reducing time to diagnosis is a high priority for The ALS Association," said Dr. Jill Yersak, vice president of mission strategy at The ALS Association.
  • There is no one test or procedure to ultimately establish the diagnosis of ALS.

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

Monday, September 20, 2021 - 6:15pm

This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).

Key Points: 
  • This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).
  • We first suspected that masitinib may generate improved survival in certain subgroups through observation of patients enrolled in study AB10015 at the Vall d'Hebron Hospital's ALS Unit [2].
  • 2020;21(1-2):5-14. doi:10.1080/21678421.2019.1632346
    [2] Gamez J. Vall dHebron participates in an international study to validate masitinib for amyotrophic lateral sclerosis treatment.
  • In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.

PathMaker Neurosystems Announces Receipt of NIH Grant For Application of its Non-Invasive Neuromodulation Technology to Amyotrophic Lateral Sclerosis (ALS)

Monday, September 20, 2021 - 6:00pm

There is tremendous unmet medical need for new treatment options for ALS, said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer at PathMaker.

Key Points: 
  • There is tremendous unmet medical need for new treatment options for ALS, said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer at PathMaker.
  • Only 3 drugs are currently FDA-approved for the treatment of ALS, but their effectiveness is limited.
  • We are hopeful that a non-invasive approach to suppressing overactive motor neurons involved in ALS can offer a new modality for treating this devastating disease.
  • PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of patients with serious neurological disorders such as stroke and amyotrophic lateral sclerosis (ALS).

Monument Announces Completion of Upscaled Phase 1 Drilling in the Field at the Murchison Gold Project

Monday, September 20, 2021 - 1:30pm

In addition, the drilling tested the strike continuation at Munro Bore Extension that is adjacent to Munro Bore (not owned by Monument).

Key Points: 
  • In addition, the drilling tested the strike continuation at Munro Bore Extension that is adjacent to Munro Bore (not owned by Monument).
  • All drilling completed by Monument utilized the following procedures and methodologies and was carried out under the supervision of Monument personnel.
  • The project area covers the eastern margin of the Meekatharra-Wydgee greenstone belt within the north-eastern Murchison domain.
  • Monument Mining Limited (TSX-V: MMY, FSE:D7Q1) is an established Canadian gold producer that owns and operates the Selinsing Gold Mine in Malaysia.

REPEAT – Major Precious Metals Completes Over 8,400m Resource Definition Program at Skaergaard

Friday, September 17, 2021 - 12:45pm

A total of 32 diamond drill holes (8,195 m) were completed in several key target areas in the northern part of Skaergaard.

Key Points: 
  • A total of 32 diamond drill holes (8,195 m) were completed in several key target areas in the northern part of Skaergaard.
  • Tony Williams, Chairman and CEO of Major Precious Metals commented, We are very pleased to have successfully completed this phase of the evaluation at Skaergaard.
  • We are reviving Skaergaard at a time when prices for Platinum Group Metals, and Palladium in particular, are robust and market fundamentals appear strong going forward.
  • All scientific and technical information contained in this news release was prepared and approved by Paul Tnire, P.Geo., President of Major Precious Metals Corp, who is a Qualified Person as defined in NI 43-101.

Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021

Friday, September 17, 2021 - 12:00pm

Clenes Phase 2 REPAIR program achieved a statistically significant increase in its primary endpoint, the mean change in brain NAD+/NADH ratio (p=0.037).

Key Points: 
  • Clenes Phase 2 REPAIR program achieved a statistically significant increase in its primary endpoint, the mean change in brain NAD+/NADH ratio (p=0.037).
  • In the REPAIR-PD study, the trend in NAD+/NADH ratio improvement was driven by both increased NAD+ and decreased NADH.
  • Robert Glanzman, MD FAAN, Clenes Chief Medical Officer, commented, We are very pleased to share our results with the Parkinsons treatment community at the MDS Virtual Congress.
  • The International Parkinson and Movement Disorder Society (MDS) is a professional society of more than 11,000 clinicians, scientists and other healthcare professionals dedicated to improving the care of patients with movement disorders through education and research.